从四年到四周 中国罕见病“确诊难”正加速破局

Core Insights - The report highlights that there are over 4,000 known rare diseases in China, affecting approximately 20 million patients, indicating that rare diseases are a significant public health issue rather than a marginal medical concern [1] - In 2025, China approved around 48 rare disease medications, with more than 17 coming from domestic companies, reflecting a shift towards local innovation in rare disease treatment [1] Group 1: Diagnosis and Treatment Improvements - The average diagnosis time for rare disease patients has been reduced from four years to less than four weeks, with costs cut by 90% [3] - The establishment of over 40 rare disease diagnostic centers across various hospitals has facilitated the implementation of multidisciplinary treatment (MDT) services [3][4] - The National Health Commission has emphasized rare diseases in its annual medical quality improvement goals, promoting cross-institutional collaboration to address misdiagnosis and delayed diagnosis [2][3] Group 2: AI Innovations in Rare Disease Diagnosis - The DeepRare AI model, developed by Shanghai Jiao Tong University, has achieved a diagnostic accuracy of 57.18% based solely on clinical symptoms, significantly improving upon previous models [4][5] - Other AI models, such as "Nezha·Lingtong" and "Xiehe·Taichu," have been introduced to provide rapid diagnostic support and tailored solutions for rare diseases, indicating a comprehensive approach to AI in this field [6] - The proliferation of AI tools in rare disease diagnosis aims to enhance screening capabilities, particularly in grassroots medical settings where access to genetic testing is limited [5][7] Group 3: Policy and Industry Implications - The integration of AI and big data into rare disease diagnosis is seen as a complementary approach to traditional clinical practices, aiming to improve early diagnosis rates and accessibility of information [7] - As the policy framework for rare diseases in China continues to develop, the collaboration between technology companies and public health objectives will be crucial for enhancing the overall healthcare system [7]